期刊
JOURNAL OF PHYSIOLOGY-LONDON
卷 596, 期 16, 页码 3493-3503出版社
WILEY
DOI: 10.1113/JP274492
关键词
-
资金
- Lui Che Woo Institute of Innovative Medicine (CARE program)
- Research Grants Council of Hong Kong [GRF 14117815, 14121816, 14163317, C7018-16G, TRS T12-402/13N]
- Health and Medical Research Fund [03140486, 14152321]
Transforming growth factor-beta (TGF-beta) is the key player in tissue fibrosis. However, antifibrotic therapy targeting this multifunctional protein may interfere with other physiological processes to cause side effects. Thus, precise therapeutic targets need to be identified by further understanding the underlyingmechanisms of TGF-beta 1 signalling during fibrogenesis. Equilibrium of Smad signalling is crucial for TGF-beta-mediated renal fibrosis, where Smad3 is pathogenic but Smad2 and Smad7 are protective. The activation of TGF-beta 1/Smad signalling triggers extracellular matrix deposition, and local myofibroblast generation and activation. Mechanistic studies have shown that TGF-beta/Smad3 transits the microRNA profile from antifibrotic to profibrotic and therefore promotes renal fibrosis via regulating non-coding RNAs at transcriptional levels. More importantly, disease-specific Smad3-dependent long non-coding RNAs have been recently uncovered from mouse kidney disease models and may represent novel precision therapeutic targets for chronic kidney disease. In this review, mechanisms of TGF-beta-driven renal fibrosis via non-coding RNAs and their translational capacities will be discussed in detail.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据